Alpha Tau Medical Ltd. reported research and development expenses of $22.5 million for the nine months ended September 30, 2025, up from $19.5 million in the same period in 2024, primarily due to increased employee compensation, benefits, and project costs. The company had a cash, cash equivalents, and deposits balance of $75.9 million as of the end of the third quarter of 2025. Key business developments during the period included the receipt of a radioactive material license for its New Hampshire manufacturing facility, progress in U.S. multi-center pilot studies for pancreatic cancer, and ongoing patient recruitment for its pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-113127), on November 20, 2025, and is solely responsible for the information contained therein.